Apreszine 25/Apreszine 50 Use In Pregnancy & Lactation

Pregnancy: Apreszine 25: Safety use of hydralazine in pregnancy has not been established. Hydralazine should not be used during pregnancy unless the possible benefits outweigh the potential risks to the fetus.
Apreszine 50: Hydralazine readily crosses the placenta with serum concentrations in the foetus being equal to or greater than those in the mother. Animal studies have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). No serious adverse effects in human pregnancy have been reported with hydralazine use during the third trimester. Thrombocytopenia, leucopenia, petechial bleeding and haematomas have been reported in new-borns whose mother took hydralazine, though these symptoms resolved spontaneously in one to three weeks. Hydralazine should be avoided during the first and second trimesters of pregnancy but may be used later in pregnancy if the mother or foetus is at risk (e.g. pre-eclampsia, eclampsia) or if no safer alternative is available.
Lactation: Apreszine 25: It is not known whether hydralazine is distributed into breast milk. Because many drugs are distributed into milk, the drug should be used with caution in nursing women.
Apreszine 50: Hydralazine passes into breast milk but reports to date have not indicated adverse effects on the infant. Breast-fed infants of mothers taking hydralazine should be observed for possible adverse effects.